Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALTITUDE: Real-world Prophylactic Treatment With Efanesoctocog Alfa in Haemophilia A
NCT06940830Phase 4Active, not recruiting
- Sponsor
- Sobi
- Start
- May 2025
- Primary completion
- Dec 2028
- Modality
- Fc-Fusion Proteins
- Countries
- 8
01
Overview
Phase 4, open-label, single-arm trial of efanesoctocog alfa in hemophilia A, sponsored by Sobi. Primary endpoint: Annualized joint bleeding rate at Month 36. Started May 2025; status: active, not recruiting.
02
Drugs
efanesoctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT06940830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06940830.